CpG ODN and ISCOMATRIX Adjuvant: A Synergistic Adjuvant Combination Inducing Strong T-Cell IFN-γResponses
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CpG ODN and ISCOMATRIX Adjuvant: A Synergistic Adjuvant Combination Inducing Strong T-Cell IFN-γResponses
Authors
Keywords
-
Journal
Biomed Research International
Volume 2013, Issue -, Pages 1-11
Publisher
Hindawi Limited
Online
2013-03-24
DOI
10.1155/2013/636847
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- ISCOMATRIX Adjuvant Induces Efficient Cross-Presentation of Tumor Antigen by Dendritic Cells via Rapid Cytosolic Antigen Delivery and Processing via Tripeptidyl Peptidase II
- (2014) M. Schnurr et al. JOURNAL OF IMMUNOLOGY
- CpG DNA as a vaccine adjuvant
- (2011) Christian Bode et al. Expert Review of Vaccines
- ISCOMATRIX vaccines mediate CD8+ T-cell cross-priming by a MyD88-dependent signaling pathway
- (2011) Nicholas S Wilson et al. IMMUNOLOGY AND CELL BIOLOGY
- Recombinant glycoprotein B vaccine formulation with Toll-like receptor 9 agonist and immune-stimulating complex induces specific immunity against multiple strains of cytomegalovirus
- (2011) V. Dasari et al. JOURNAL OF GENERAL VIROLOGY
- ISCOMATRIX Adjuvant Combines Immune Activation with Antigen Delivery to Dendritic Cells In Vivo Leading to Effective Cross-Priming of CD8+ T Cells
- (2011) P. Duewell et al. JOURNAL OF IMMUNOLOGY
- Marked enhancement of the immune response to BioThrax® (Anthrax Vaccine Adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers
- (2011) Dianna Rynkiewicz et al. VACCINE
- Improving the Immunogenicity of Pneumococcal Conjugate Vaccine in HIV‐Infected Adults with a Toll‐Like Receptor 9 Agonist Adjuvant: A Randomized, Controlled Trial
- (2010) Ole S. Søgaard et al. CLINICAL INFECTIOUS DISEASES
- Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX™ vaccine: A phase I study in healthy volunteers
- (2010) Debbie Drane et al. Human vaccines & immunotherapeutics
- An ISCOM vaccine combined with a TLR9 agonist breaks immune evasion mediated by regulatory T cells in an orthotopic model of pancreatic carcinoma
- (2010) Collin Jacobs et al. INTERNATIONAL JOURNAL OF CANCER
- Regulatory T-Cell-Mediated Attenuation of T-Cell Responses to the NY-ESO-1 ISCOMATRIX Vaccine in Patients with Advanced Malignant Melanoma
- (2009) T. Nicholaou et al. CLINICAL CANCER RESEARCH
- Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant
- (2009) Eugene Maraskovsky et al. IMMUNOLOGY AND CELL BIOLOGY
- A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel® with CPG 7909, using two different formulations and dosing intervals
- (2009) Ruth D. Ellis et al. VACCINE
- A randomized and controlled Phase 1 study of the safety and immunogenicity of the AMA1-C1/Alhydrogel®+CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults
- (2009) Issaka Sagara et al. VACCINE
- CPG 7909 Adjuvant plus Hepatitis B Virus Vaccination in HIV‐Infected Adults Achieves Long‐Term Seroprotection for Up to 5 Years
- (2008) C. L. Cooper et al. CLINICAL INFECTIOUS DISEASES
- Phase 1 Trial of AMA1-C1/Alhydrogel plus CPG 7909: An Asexual Blood-Stage Vaccine for Plasmodium falciparum Malaria
- (2008) Gregory E. D. Mullen et al. PLoS One
- Protection afforded against aerosol challenge by systemic immunisation with inactivated Francisella tularensis live vaccine strain (LVS)
- (2007) J.E. Eyles et al. MICROBIAL PATHOGENESIS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started